845751-86-2

Upstream product

• 845751-70-4 7-Bromo-2-methyl-2H-indazole-3-carbaldehyde 
• 68716-47-2 2,4-dichlorophenylboronic acid 
• 701910-14-7 7-bromo-2-methyl-2H-indazole 
• 53857-58-2 7-bromo-1H-indazole 

Downstream Products

• 845750-74-5 7-(2,4-Dichloro-phenyl)-2-methyl-2H-indazole-3-carbonitrile 
• 845751-55-5 [7-(2,4-dichloro-phenyl)-2-methyl-2H-indazol-3-yl]-methanol 
• 952236-10-1 2-{[7-(2,4-Dichlorophenyl)-2-methyl-2H-indazol-3-yl]-hydroxymethyl}-imidazole-1-sulfonic acid dimethylamide 
• 952236-44-1 7-(2,4-dichloro-phenyl)-3-(2-methoxy-vinyl)-2-methyl-2H-indazole 
• 845751-85-1 N-[7-(2,4-dichloro-phenyl)-2-methyl-2H-indazol-3-ylmethyl]-N-methyl-acetamide 
• 845750-73-4 [7-(2,4-Dichloro-phenyl)-2-methyl-2H-indazol-3-yl]-acetonitrile 
• 845751-83-9 C₁₅H₁₁BrCl₂N₂ 
• 845751-90-8 C₂₀H₂₀Cl₂N₄O₂ 

Relevant academic research and scientific papers

Heterocyclic GABAA subtype selective receptor modulators

The present invention provides a compound of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Y, Ar, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, methods of usin

GABANERGIC MODULATORS

This invention relates to the use of compounds of benzoindazole derivatives salts and solvates thereof for the preparation of a medicament for modulating alpha2 subtype GABA A receptors. The invention further relates to novel heterocyclic compounds and pharmaceutical compositions containing said compounds. In addition the invention relates to the use of compounds of formula (I) salts and solvates thereof for the preparation of a medicament for the treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder or pain.